Pancreatic Cancer Research

ResearcherGuy's HospitalActive in the last 2 years

Andreas A. Prachalias

ORCID-verified (high confidence, 0.95), identity_conf@1As of 8 November 2026

Matched on ORCID iD 0000-0001-9967-634X; OpenAlex author ID A5029176304. Sources: OpenAlex.

Their work

Papers
9 (first author 0, last author 4)
Trials
0
Grants
0
Labs led
1
Collaborators
52
Papers, trials and grants by year

2021: 2 papers · 2022: 1 paper · 2023: 1 paper · 2024: none · 2025: 1 paper · 2026: 4 papers

Papers 9

  1. Complete pathological response in metastatic pancreatic adenocarcinoma following neoadjuvant therapy. Last author DOI 10.1016/j.pan.2025.11.018↗
  2. Can negative lymph node involvement and resection-free margins (ypT1-3N0R0) compete the disease-free survival benefit of a pathologic complete response (ypT0N0… Last author DOI 10.1016/j.pan.2025.11.020↗
  3. Vanishing liver metastases in pancreatic cancer: A case report. Last author DOI 10.3892/ol.2026.15691↗
  4. Apparent Long-Term Cure Following Conversion Therapy for Initially Unresectable Pancreatic Ductal Adenocarcinoma: A Case Report. Last author DOI 10.7759/cureus.105912↗
  5. Delayed surgery during the Covid-19 pandemic did not affect long-term outcomes of pancreatic adenocarcinoma. Co-author DOI 10.1016/j.suronc.2024.102169↗
  6. Immediate surgery compared with short-course neoadjuvant gemcitabine plus capecitabine, FOLFIRINOX, or chemoradiotherapy in patients with borderline resectable… Co-author DOI 10.1016/s2468-1253(22)00348-x↗
  7. USP25 promotes pathological HIF-1-driven metabolic reprogramming and is a potential therapeutic target in pancreatic cancer. Co-author DOI 10.1038/s41467-022-29684-9↗
  8. Margin ACcentuation for resectable Pancreatic cancer using Irreversible Electroporation - Results from the MACPIE-I study. Co-author DOI 10.1016/j.ejso.2021.05.024↗
  9. Impact of SARS-CoV-2 pandemic on pancreatic cancer services and treatment pathways: United Kingdom experience. Co-author DOI 10.1016/j.hpb.2021.03.003↗

Closest collaborators

The 25 strongest of 52 by collab_strength@1: shared papers, trials and grants, recent and small-team work weighing most.

  1. Evangelia Florou · 4 shared papers, 2026 · strength 1.68
  2. Yoh Zen · 5 shared papers, 2021–2026 · strength 1.48
  3. Paul J. Ross · 3 shared papers, 2021–2026 · strength 0.66
  4. Krishna V Menon · 3 shared papers, 2021–2025 · strength 0.43
  5. Ricky Harminder Bhogal · 2 shared papers, 2021–2025 · strength 0.32
  6. Albasheer Hamadalnile · 1 shared paper, 2025 · strength 0.24
  7. Jiao Li · 1 shared paper, 2025 · strength 0.24
  8. C. Schneider · 1 shared paper, 2025 · strength 0.24
  9. Debashis Sarker · 2 shared papers, 2021–2022 · strength 0.23
  10. Iain Stephen Tait · 2 shared papers, 2021–2023 · strength 0.20
  11. Bilal A. Al-Sarireh · 2 shared papers, 2021–2023 · strength 0.20
  12. Keith John Roberts · 2 shared papers, 2021–2023 · strength 0.20
  13. Jessica Kristine Nelson · 1 shared paper, 2022 · strength 0.12
  14. Theodore Evan · 1 shared paper, 2022 · strength 0.12
  15. Axel Behrens · 1 shared paper, 2022 · strength 0.12
  16. Yuk Ting Ma · 1 shared paper, 2023 · strength 0.12
  17. Paula Ghaneh · 1 shared paper, 2023 · strength 0.12
  18. Janet Shirley Graham · 1 shared paper, 2023 · strength 0.12
  19. Irfan Ahmed · 1 shared paper, 2023 · strength 0.12
  20. Markus Wolfgang Büchler · 1 shared paper, 2023 · strength 0.12
  21. Daniel H. Palmer · 1 shared paper, 2023 · strength 0.12
  22. Thilo Hackert · 1 shared paper, 2023 · strength 0.12
  23. Somnath Mukherjee · 1 shared paper, 2023 · strength 0.12
  24. Derek A O'Reilly · 1 shared paper, 2023 · strength 0.12
  25. Christoph Springfeld · 1 shared paper, 2023 · strength 0.12

How to reach this person

A chain of introductions through people who have published, run trials or held grants together (warm_path@1: fewest links first, then the strongest). Built from public records only; no contact details are kept.